2. Academic Validation
  3. Discovery of Imidazo[1,2- a]pyrazine Derivatives as Potent ENPP1 Inhibitors

Discovery of Imidazo[1,2- a]pyrazine Derivatives as Potent ENPP1 Inhibitors

  • J Med Chem. 2024 Oct 24;67(20):18317-18333. doi: 10.1021/acs.jmedchem.4c01634.
Shiping Zhan 1 2,  Yingying Zhang 3 4,  Tian Cao 1 5,  Ruirui Yang 6,  Qiang Wang 1,  Lin Huang 1,  Rongrong Cui 6,  Jie Yu 6,  Haifang Meng 1,  Yitian Wang 6,  Sulin Zhang 6,  Mingyue Zheng 6 3 4,  Xiaowei Wu 6 1 2
Affiliations

Affiliations

  • 1 Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
  • 2 School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.
  • 3 School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China.
  • 4 The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
  • 5 School of Pharmacy, Guizhou Medical University, Guiyang 550014, China.
  • 6 Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
PMID: 39357030 DOI: 10.1021/acs.jmedchem.4c01634
Abstract

ENPP1 acts as a negative regulator of the cGAS-STING pathway through the hydrolysis of 2'3'-cGAMP. Inhibitors of ENPP1 are regarded as promising agents for stimulating the immune response in Cancer Immunotherapy. This study describes the identification and optimization of imidazo[1,2-a]pyrazine derivative 7 as a highly potent and selective ENPP1 inhibitor. Compound 7 demonstrated substantial inhibitory activity against ENPP1 with an IC50 value of 5.70 or 9.68 nM while showing weak inhibition against ENPP2 and ENPP3. Furthermore, compound 7 was shown to enhance the mRNA expression of cGAMP-induced STING pathway downstream target genes, such as IFNB1, CXCL10, and IL6. In vivo pharmacokinetic and antitumor studies showed promising results, with 7 not only exhibiting efficient pharmacokinetic properties but also enhancing the antitumor efficacy of the anti-PD-1 antibody. Treatment with 7 (80 mg/kg) combined with anti-PD-1 antibody achieved a tumor growth inhibition rate of 77.7% and improved survival in a murine model.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z